Global Tumor Genomics Market

Global Tumor
Genomics Market
Focus on Products, Techniques,
Applications, End User, Cancer Type,
14 Countries Data, Industry Insights
and Competitive Landscape-
Analysis and Forecast, 2019-2028
May 2020
TOC

Global Tumor Genomics Market
All rights reserved at BIS Research 2
BIS Research is a leading market intelligence and technology research company. BIS Research
publishes in-depth market intelligence reports focusing on the market estimations, technology
analysis, emerging high-growth applications, deeply segmented granular country-level market data
and other important market parameters useful in the strategic decision making for senior
management. BIS Research provides multi-client reports, company profiles, databases, and custom
research services.
Copyright © 2020 BIS Research
All Rights Reserved. This document contains highly confidential information and is the sole property
of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all
contents of this document is strictly prohibited. Access to this information is provided exclusively for
the benefit of the people or organization concerned. It may not be accessed by, or offered whether
for sale or otherwise to any third party.

Table of Contents
Executive Summary……………………………………………...……………. 22
1. Product Definition ..............................................................................................36
1.1 Inclusion and Exclusion .............................................................................. 36
2. Research Scope..................................................................................................38
2.1 Scope of the Study....................................................................................... 38
2.2 Key Questions Answered in the Report..................................................... 39
3. Research Methodology ......................................................................................40
3.1 Global Tumor Genomics: Research Methodology .................................... 40
3.2 Primary Data Sources.................................................................................. 41
3.3 Secondary data sources.............................................................................. 42
3.4 Data Triangulation........................................................................................ 44
3.5 Segmentation of the Global Tumor Genomics Market.............................. 48
3.6 Inclusion and Exclusion .............................................................................. 48
3.7 Base Year and Forecast Year...................................................................... 49
4. Global Tumor Genomics Market .......................................................................50
4.1 Market Overview........................................................................................... 50
4.2 Introduction to Tumor Genomics ............................................................... 51
4.3 Evolution of Tumor Genomic Techniques ................................................. 52
4.4 Global Market Scenario and Key Technology Trends............................... 53
5. Market Dynamics ................................................................................................55
5.1 Introduction .................................................................................................. 55
5.2 Impact Analysis............................................................................................ 55
5.3 Market Drivers .............................................................................................. 56
5.3.1 Rising Government Initiatives and Projects ................................... 56
5.3.2 Increasing Incidence of Cancer........................................................ 57
5.3.3 Increasing Number of Product Approval and Launches................ 58
5.3.4 Ever Expanding Application Areas for Genomics .......................... 59

5.3.5 Increasing Use of Biomarkers in Cancer Profiling ......................... 61
5.4 Market Restraints......................................................................................... 61
5.4.1 High Cost of Genomic Equipment ................................................... 61
5.4.2 Lack of Unified Framework for Data Integration............................. 62
5.5 Market Opportunities ................................................................................... 62
5.5.1 Growing Prominence for Precision Medicine ................................. 62
5.5.2 Increasing Demand for Point-of-Care Diagnostics......................... 63
6. Industry Insights.................................................................................................64
6.1 Regulatory Requirements............................................................................ 64
6.1.1 Regulatory Framework in the U.S. ................................................... 66
6.1.1.1 Guidelines Published in FY2018.......................................................... 66
6.1.1.2 Guidelines Published in FY2016.......................................................... 66
6.1.2 Europe................................................................................................ 67
6.1.3 Japan.................................................................................................. 68
6.2 Patent Analysis ............................................................................................ 69
7. Competitive Landscape .....................................................................................72
7.1 Key Developments and Strategies ............................................................. 73
7.1.1 Partnerships and Alliances .............................................................. 74
7.1.2 New Product Launches..................................................................... 75
7.1.3 Mergers and Acquisition Activities.................................................. 76
7.1.4 Business Expansions ....................................................................... 77
7.1.5 Others................................................................................................. 77
7.2 Market Share Analysis................................................................................. 79
7.2.1 Market Share Analysis (by Company) ............................................. 79
7.3 Growth Share Analysis................................................................................ 80
7.3.1 Growth Share Matrix (by Company)................................................. 80
8. Global Tumor Genomics Market (by Product) .................................................83
8.1 Assays and Kits ........................................................................................... 86
8.2 Instrument..................................................................................................... 87
9. Global Tumor Genomics Market (by Technique) .............................................89

9.1 Next Generation Sequencing (NGS) ........................................................... 91
9.2 Polymerase Chain Reaction (PCR) ............................................................. 92
9.3 Microarray..................................................................................................... 93
9.4 In-Situ Hybridization (ISH)........................................................................... 95
9.5 Immunohistochemistry (IHC) ...................................................................... 96
9.6 Other Technologies (Mass Spectrometry and Flow Cytometry) .............. 97
10. Global Tumor Genomics Market (by Application) ...........................................99
10.1 Diagnostics and Monitoring.......................................................................100
10.2 Drug Discovery and Development.............................................................101
10.3 Biomarker Discovery ..................................................................................103
11. Global Tumor Genomics Market (by End User) .............................................105
11.1 Academics and Research Organizations..................................................106
11.2 Hospitals and Ambulatory Clinics .............................................................108
11.3 Clinical and Diagnostic Laboratories ........................................................110
11.4 Biotechnology and Pharmaceutical Companies ......................................111
12. Global Tumor Genomics Market (by Cancer Type) .......................................113
12.1 Leukemia......................................................................................................115
12.2 Breast Cancer..............................................................................................116
12.3 Melanoma.....................................................................................................117
12.4 Colon Cancer...............................................................................................118
12.5 Lung Cancer ................................................................................................120
12.6 Prostate Cancer...........................................................................................121
12.7 Head and Neck Cancer ...............................................................................122
12.8 Others (Ovarian, Pancreatic, and Testicular)............................................124
13. Global Tumor Genomics Market (By Region) ................................................126
13.1 North America .............................................................................................128
13.1.1 North America Tumor Genomics Market (by Country)..................130
13.1.2 U.S. ....................................................................................................131
13.1.3 Canada ..............................................................................................133
13.2 Europe..........................................................................................................134

13.2.1 Europe Tumor Genomics Market (by Country) ..............................137
13.2.2 Germany............................................................................................138
13.2.3 U.K. ....................................................................................................139
13.2.4 France................................................................................................140
13.2.5 Italy ....................................................................................................142
13.2.6 Spain..................................................................................................143
13.2.7 Netherlands.......................................................................................144
13.2.8 Rest-of-Europe..................................................................................145
13.3 Asia-Pacific (APAC) ....................................................................................147
13.3.1 Asia-Pacific Tumor Genomics Market (by Country) ......................150
13.3.2 China .................................................................................................151
13.3.3 Japan.................................................................................................152
13.3.4 Australia............................................................................................153
13.3.5 India...................................................................................................155
13.3.6 Rest-of-Asia-Pacific..........................................................................156
13.4 Rest-of-the-World........................................................................................158
13.4.1 Rest-of-the-World Tumor Genomics Market (by Country) ............160
13.4.2 Latin America....................................................................................161
13.4.3 Middle East & Africa.........................................................................162
14. Company Profiles.............................................................................................164
14.1 Abbott Laboratories....................................................................................164
14.1.1 Company Overview ..........................................................................164
14.1.2 Role of Abbott Laboratories in the Global Tumor Genomics
Market................................................................................................165
14.1.3 Financials..........................................................................................166
14.1.4 Key Insights About Financial Health of the Company ..................169
14.1.5 SWOT Analysis.................................................................................170
14.2 Agilent Technologies, Inc...........................................................................171
14.2.2 Role of Agilent Technologies, Inc. in the Global Tumor
Genomics Market..............................................................................171
14.2.3 Financials..........................................................................................172

14.2.5 SWOT Analysis.................................................................................176
14.3 Bio-Rad Laboratories, Inc...........................................................................177
14.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Tumor
Genomics Market..............................................................................177
14.3.3 Financials..........................................................................................178
14.3.5 SWOT Analysis.................................................................................182
14.4 Danaher Corporation ..................................................................................183
14.4.2 Role of Danaher Corporation in the Global Tumor Genomics
Market................................................................................................183
14.4.3 Financials..........................................................................................184
14.4.5 SWOT Analysis.................................................................................187
14.5 F. Hoffmann-La Roche Ltd .........................................................................188
14.5.2 Role of F. Hoffmann-La Roche Ltd in the Global Tumor
Genomics Market..............................................................................188
14.5.3 Financials..........................................................................................190
14.5.5 SWOT Analysis.................................................................................193
14.6 Fluidigm Corporation..................................................................................194
14.6.2 Role of Fluidigm Corporation in the Global Tumor Genomics
Market................................................................................................194
14.6.3 Financials..........................................................................................195
14.6.5 SWOT Analysis.................................................................................199
14.7 General Electric Company..........................................................................200

14.7.2 Role of General Electric Company in the Global Tumor
Genomics Market..............................................................................200
14.7.3 Financials..........................................................................................201
14.7.5 SWOT Analysis.................................................................................205
14.8 Illumina, Inc. ................................................................................................206
14.8.2 Role of Illumina, Inc. in the Global Tumor Genomic Market .........206
14.8.3 Financials..........................................................................................208
14.8.5 SWOT Analysis.................................................................................211
14.9 Merck KGaA.................................................................................................212
14.9.2 Role of Merck KGaA in the Global Tumor Genomics Market........212
14.9.3 Financials..........................................................................................213
14.9.5 SWOT Analysis.................................................................................217
14.10 Myriad Genetics, Inc. ..................................................................................218
14.10.2 Role of Myriad Genetics, Inc. in the Global Tumor Genomics
Market................................................................................................218
14.10.3 Financials..........................................................................................220
14.10.5 SWOT Analysis.................................................................................223
14.11 Pacific Biosciences of California, Inc........................................................224
14.11.2 Role of Pacific Biosciences of California, Inc. in the Global
Tumor Genomics Market .................................................................224
14.11.3 Financials..........................................................................................225
14.11.5 SWOT Analysis.................................................................................229
14.12 PerkinElmer .................................................................................................230

14.12.2 Role of PerkinElmer in the Global Tumor Genomics Market........230
14.12.3 Financials..........................................................................................231
14.12.4 Key Insights about Financial Health of the Company ...................234
14.12.5 SWOT Analysis.................................................................................235
14.13 QIAGEN........................................................................................................236
14.13.2 Role of QIAGEN in the Global Tumor Genomics Market...............236
14.13.3 Financials..........................................................................................238
14.13.5 SWOT Analysis.................................................................................242
14.14 Siemens Healthineers AG...........................................................................243
14.14.2 Role of Siemens Healthineers AG in the Global Tumor
Genomics Market..............................................................................243
14.14.3 Financials..........................................................................................245
14.14.5 SWOT Analysis.................................................................................249
14.15 Thermo Fisher Scientific Inc. .....................................................................250
14.15.2 Role of Thermo Fisher Scientific Inc. in the Global Tumor
Genomics Market..............................................................................250
14.15.3 Financials..........................................................................................252
14.15.4 Key Insights on the Financial Health of the Company ..................255
14.15.5 SWOT Analysis.................................................................................256

List of Tables
Table 1: Key Product Launches Between May 2017-February 2020 ................................................ 25
Table 5.1: Impact Analysis of Market Drivers...................................................................................... 56
Table 5.2: Impact analysis of Market Restraints ................................................................................. 56
Table 5.3: Number of Product Launches (2018-2020)........................................................................ 59
Table 5.4: Number of Product Approvals (2018 and 2019)................................................................ 59
Table 6.1: List of Major Regulatory Bodies and Associations across the World................................ 64
Table 6.2: Global Tumor Genomics Market: Patent Analysis............................................................. 69
Table 8.1: Competitive Benchmarking by Product and Technique .................................................... 84

List of Figures
Figure 1: Percentage of Cancer Deaths, by Type: 2007-2020........................................................... 22
Figure 2: Global Tumor Genomics Market Value, 2018-2028............................................................ 24
Figure 3: Drivers and Restraints of Global Tumor Genomics Market................................................. 26
Figure 4: Share of Key Developments and Strategies, January 2017-February 2020...................... 27
Figure 5: Global Tumor Genomics Market (by Product), 2018-2028 ................................................. 28
Figure 6: Global Tumor Genomics Market (by Technique), 2018-2028............................................. 29
Figure 7: Global Tumor Genomics Market (by Application), 2018-2028............................................ 30
Figure 8: Global Tumor Genomics Market (by End User), 2018-2028............................................... 31
Figure 9: Global Tumor Genomics Market (by Cancer Type), 2018-2028......................................... 32
Figure 10: Global Tumor Genomics Market (by Region): 2019 and 2028......................................... 33
Figure 3.1: Global Tumor Genomics Market Research Methodology................................................ 41
Figure 3.2: Primary Research .............................................................................................................. 42
Figure 3.3: Secondary Research ......................................................................................................... 43
Figure 3.4: Data Triangulation.............................................................................................................. 44
Figure 3.5: Top-Down Approach (Segment-Wise Analysis)............................................................... 45
Figure 3.6: Bottom-up Approach (Segment-Wise Analysis)............................................................... 45
Figure 3.7: Assumptions and Limitations............................................................................................. 46
Figure 3.8: Assumptions and Limitations............................................................................................. 47
Figure 3.9: Segmentation of the Global Tumor Genomics Market..................................................... 48
Figure 4.1: Evolution of Tumor Genomic Techniques......................................................................... 52
Figure 4.2: Global Tumor Genomics Market Size, 2018-2028........................................................... 54
Figure 5.1: Incidence of Different Cancers (2014-2017)..................................................................... 58
Figure 7.1: Competitive Landscape, January 2017-February 2020 ................................................... 73
Figure 7.2: Share of Key Developments and Strategies, January 2017-February 2020................... 74
Figure 7.3: Partnerships and Alliances (by Company), January 2017-February 2020...................... 75
Figure 7.4: New Product Launches (by Company), January 2017-February 2020 ........................... 76
Figure 7.5: Others (by Company), January 2017-February 2020 ...................................................... 78
Figure 7.6: Market Share Analysis for the Global Tumor Genomics Market, by Company (2019).. 79
Figure 7.7: Growth Share Matrix: Global Tumor Genomics Market (by Company), 2018-2019...... 81

Figure 8.1: Global Tumor Genomics Market (by Product).................................................................. 83
Figure 8.2: Global Tumor Genomics Market (by Product), 2018-2028 .............................................. 84
Figure 8.3: Global Tumor Genomics Market for Assays and Kits, 2018-2028................................... 86
Figure 8.4: Global Tumor Genomics Market for Instruments, 2018-2028.......................................... 87
Figure 9.1: Global Tumor Genomics Market, by Techniques............................................................. 89
Figure 9.2: Global Tumor Genomics Market (by Technique), 2018-2028.......................................... 90
Figure 9.3: Global Tumor Genomics Market (Technique: Next-Generation Sequencing),
2018-2028 ................................................................................................................................ 91
Figure 9.4: Global Tumor Genomics Market (Technique: Polymerase Chain Reaction),
2018-2028 ................................................................................................................................ 93
Figure 9.5: Global Tumor Genomics Market (Technique: Microarray) , 2018-2028.......................... 94
Figure 9.6: Global Tumor Genomics Market (Technique: In-Situ Hybridization), 2018-2028 ........... 95
Figure 9.7: Global Tumor Genomics Market (Technique: Immunohistochemistry), 2018-2028 ...... 96
Figure 9.8: Global Tumor Genomics Market (Technique: Other Technologies {Mass
Spectrometry and Flow Cytometry}), 2018-2028.................................................................... 98
Figure 10.1: Global Tumor Genomics Market, by Application ............................................................ 99
Figure 10.2: Global Tumor Genomics Market (by Application), 2018-2028....................................... 99
Figure 10.3: Global Tumor Genomics Market (Application: Diagnostics and Monitoring),
2018-2028 .............................................................................................................................. 101
Figure 10.4: Global Tumor Genomics Market (Application: Drug Discovery and Development),
2018-2028 .............................................................................................................................. 102
Figure 10.5: Global Tumor Genomics Market (Application: Biomarker Discovery), 2018-2028 .... 103
Figure 11.1: Global Tumor Genomics Market, by End User............................................................. 105
Figure 11.2: Global Tumor Genomics Market (by End User), 2018-2028 ....................................... 106
Figure 11.3: Global Tumor Genomics Market (End User: Academics and Research Organizations),
2018-2028 .............................................................................................................................. 108
Figure 11.4: Global Tumor Genomics Market (End User: Hospitals and Ambulatory Clinics),
2018-2028 .............................................................................................................................. 109
Figure 11.5: Global Tumor Genomics Market (End User: Clinical and Diagnostic Laboratories),
2018-2028 .............................................................................................................................. 111

Figure 11.6: Global Tumor Genomics Market (End User: Biotechnology and Pharmaceutical
Company), 2018-2028........................................................................................................... 112
Figure 12.1: Global Tumor Genomics Market, by Cancer Type....................................................... 113
Figure 12.2: Global Tumor Genomics Market (by Cancer Type), 2018-2028.................................. 114
Figure 12.3: Global Tumor Genomics Market (Cancer Type: Leukemia), 2018-2028 .................... 115
Figure 12.4: Global Tumor Genomics Market (Cancer Type: Breast Cancer), 2018-2028............. 116
Figure 12.5: Global Tumor Genomics Market (Cancer Type: Melanoma), 2018-2028 ................... 118
Figure 12.6: Global Tumor Genomics Market (Cancer Type: Colon Cancer), 2018-2028.............. 119
Figure 12.7: Global Tumor Genomics Market (Cancer Type: Lung Cancer), 2018-2028 ............... 120
Figure 12.8: Global Tumor Genomics Market (Cancer Type: Prostate Cancer), 2018-2028.......... 122
Figure 12.9: Global Tumor Genomics Market (Cancer Type: Head and Neck Cancer),
2018-2028 .............................................................................................................................. 123
Figure 12.10: Global Tumor Genomics Market (Cancer Type: Others {Ovarian, Pancreatic,
and Testicular}), 2018-2028................................................................................................... 125
Figure 13.1: Global Tumor Genomics Market (by Region), 2019 and 2028.................................... 126
Figure 13.2: North America Tumor Genomics Market, 2018-2028 .................................................. 129
Figure 13.3: North America: Market Dynamics ................................................................................. 130
Figure 13.4: North America Tumor Genomics Market (by Country), 2019 and 2028...................... 130
Figure 13.5: U.S. Tumor Genomics Market, 2018-2028................................................................... 132
Figure 13.6: Canada: Tumor Genomics Market, 2018-2028............................................................ 134
Figure 13.7: Europe: Tumor Genomics Market, 2018-2028............................................................. 135
Figure 13.8: Europe: Market Dynamics............................................................................................. 136
Figure 13.9: Europe Tumor Genomics Market (by Country), 2019 and 2028.................................. 137
Figure 13.10: Germany Tumor Genomics Market, 2018-2028......................................................... 138
Figure 13.11: U.K. Tumor Genomics Market, 2018-2028................................................................. 140
Figure 13.12: France Tumor Genomics Market, 2018-2028 ............................................................ 141
Figure 13.13: Italy Tumor Genomics Market, 2018-2028 ................................................................. 142
Figure 13.14: Spain Tumor Genomics Market, 2018-2028 .............................................................. 143
Figure 13.15: Netherlands Tumor Genomics Market, 2018-2028.................................................... 145
Figure 13.16: Rest-of-Europe Tumor Genomics Market, 2018-2028............................................... 147
Figure 13.17: Asia-Pacific: Tumor Genomics Market, 2018-2028.................................................... 148

Figure 13.18: Asia-Pacific: Market Dynamics.................................................................................... 149
Figure 13.19: Asia-PacificTumor Genomics Market (by Country), 2019 and 2028 ......................... 150
Figure 13.20: China Tumor Genomics Market, 2018-2028 .............................................................. 151
Figure 13.21: Japan Tumor Genomics Market, 2018-2028.............................................................. 153
Figure 13.22: Australia Tumor Genomics Market, 2018-2028.......................................................... 154
Figure 13.23: India Tumor Genomics Market, 2018-2028................................................................ 156
Figure 13.24: Rest-of-Asia-Pacific Tumor Genomics Market, 2018-2028 ....................................... 157
Figure 13.25: Rest-of-the-World Tumor Genomics Market, 2018-2028........................................... 158
Figure 13.26: Rest-of-the-World (RoW): Market Dynamics.............................................................. 159
Figure 13.27: Rest-of-the-World Tumor Genomics Market (by Country), 2019 and 2028 .............. 160
Figure 13.28: Latin America Tumor Genomics Market, 2018-2028 ................................................. 161
Figure 13.29: Middle East & Africa Tumor Genomics Market, 2018-2028....................................... 162
Figure 14.1: Abbott Laboratories: Product Offerings for the Global Tumor Genomics Market ....... 165
Figure 14.2: Abbott Laboratories: Overall Financials, 2017-2019 .................................................... 166
Figure 14.3: Abbott Laboratories: Revenue (by Product/Service), 2017-2019................................ 167
Figure 14.4: Abbott Laboratories: Revenue (by Region), 2017-2019............................................... 168
Figure 14.5: Abbott Laboratories: R&D Expenditure, 2017-2019..................................................... 169
Figure 14.6: Abbott Laboratories: SWOT Analysis ........................................................................... 170
Figure 14.7: Agilent Technologies, Inc.: Product Offerings for the Global Tumor
Genomics Market................................................................................................................... 172
Figure 14.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019 .......................................... 172
Figure 14.9: Agilent Technologies, Inc.: Revenue (by Business Model), 2017-2019...................... 173
Figure 14.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019 .................................. 174
Figure 14.11: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019......................................... 175
Figure 14.12: Agilent Technologies, Inc.: SWOT Analysis ............................................................... 176
Figure 14.13: Bio-Rad Laboratories, Inc.: Product Offerings for the Global Tumor
Genomics Market................................................................................................................... 178
Figure 14.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018 ....................................... 178
Figure 14.15: Bio-Rad Laboratories, Inc.: Revenue (by Product/Service), 2016-2018 ................... 179
Figure 14.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018.................................. 180
Figure 14.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018 ........................................ 181

Figure 14.18: Bio-Rad Laboratories, Inc.: SWOT Analysis............................................................... 182
Figure 14.19: Danaher Corporation Product Offerings for the Global Tumor Genomics Market... 184
Figure 14.20: Danaher Corporation: Overall Financials, 2017-2019................................................ 184
Figure 14.21: Danaher Corporation: Revenue (by Product/Service), 2017-2019............................ 185
Figure 14.22: Danaher Corporation: Revenue (by Region), 2017-2019.......................................... 186
Figure 14.23: Danaher Corporation: R&D Expenditure, 2017-2019 ................................................ 186
Figure 14.24: Danaher Corporation: SWOT Analysis....................................................................... 187
Figure 14.25: F. Hoffman-La-Roche Ltd: Product Offerings for the Global Tumor
Genomics Market................................................................................................................... 189
Figure 14.26: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019....................................... 190
Figure 14.27: F. Hoffmann-La Roche Ltd: Revenue (by Product/Service), 2017-2019................... 191
Figure 14.28: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019................................. 191
Figure 14.29: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2018 ....................................... 192
Figure 14.30: F. Hoffmann-La Roche AG: SWOT Analysis.............................................................. 193
Figure14.31: Fluidigm Corporation: Overall Product Portfolio .......................................................... 195
Figure 14.32: Fluidigm Corporation: Overall Financials, 2017-2019................................................ 195
Figure 14.33: Fluidigm Corporation: Revenue (by Business Segment), 2016-2018 ....................... 196
Figure 14.34: Fluidigm Corporation: Revenue (by Region), 2016-2018 .......................................... 197
Figure 14.35: Fluidigm Corporation: R&D Expenditure, 2016-2018................................................. 198
Figure 14.36: Fluidigm Corporation: SWOT Analysis ....................................................................... 199
Figure 14.37: General Electric Company: Product Offerings for the Global Tumor
Genomics Market................................................................................................................... 201
Figure 14.38: General Electric Company: Overall Financials, 2017-2019 ....................................... 201
Figure 14.39: General Electric Company: Revenue (by Business Model), 2017-2019................... 202
Figure 14.40: General Electric Company: Revenue (by Region), 2017-2019 ................................. 203
Figure 14.41: General Electric Company: R&D Expenditure, 2017-2019........................................ 204
Figure 14.42: General Electric Company: SWOT Analysis .............................................................. 205
Figure 14.43: Illumina, Inc.: Product Offerings for the Global Tumor Genomics Market ................. 207
Figure 14.44: Illumina, Inc.: Overall Financials, 2016-2018.............................................................. 208
Figure 14.45: Illumina Inc.: Revenue (by Segment), 2016-2018...................................................... 208
Figure 14.46: Illumina, Inc.: Revenue (by Region), 2016-2018........................................................ 209

Figure 14.47: Illumina, Inc.: R&D Expenditure, 2016-2018 .............................................................. 210
Figure 14.48: Illumina, Inc.: SWOT Analysis..................................................................................... 211
Figure 14.49: Merck KGaA: Product Offerings for the Global Tumor Genomics Market................. 213
Figure 14.50: Merck KGaA: Overall Financials, 2017-2019 ............................................................. 213
Figure 14.51: Merck KGaA: Revenue (by Product/Service), 2017-2019 ......................................... 214
Figure 14.52: Merck KGaA: Revenue (by Region), 2017-2019........................................................ 215
Figure 14.53: Merck KGaA: R&D Expenditure, 2017-2019.............................................................. 216
Figure 14.54: Merck KGaA: SWOT Analysis..................................................................................... 217
Figure 14.55: Myriad Genetics, Inc.: Product Offerings for the Global Tumor Genomics Market.. 219
Figure 14.56: Myriad Genetics, Inc.: Overall Financials, 2017-2019................................................ 220
Figure 14.57: Myriad Genetics, Inc.: Revenue (by Product/Service), 2017-2019............................ 221
Figure 14.58: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019 ................................................ 222
Figure 14.59: Myriad Genetics, Inc.: SWOT Analysis....................................................................... 223
Figure 14.60: Bio-Rad Laboratories, Inc.: Overall Product Portfolio................................................. 225
Figure 14.61: Pacific Biosciences of California, Inc.: Overall Financials, 2016-2018...................... 225
Figure 14.62: Pacific Biosciences of California, Inc.: Revenue (by Product/Service), 2016-2018. 226
Figure 14.63: Pacific Biosciences of California, Inc.: Revenue (by Region), 2016-2018 ................ 227
Figure 14.64: Pacific Biosciences of California, Inc.: R&D Expenditure, 2016-2018....................... 228
Figure 14.65: Pacific Biosciences: SWOT Analysis.......................................................................... 229
Figure 14.66: PerkinElmer: Product Offerings for the Global Tumor Genomics Market ................. 231
Figure 14.67: Perkin Elmer: Overall Financials, 2017-2019 ............................................................. 231
Figure 14.68: PerkinElmer: Revenue (by Products & Services), 2017-2019................................... 232
Figure 14.69: PerkinElmer: Revenue (by Region), 2017-2019......................................................... 233
Figure 14.70: PerkinElmer: R&D Expenditure, 2017-2019............................................................... 234
Figure 14.71: PerkinElmer lnc.: SWOT Analysis............................................................................... 235
Figure 14.72: QIAGEN: Product Offerings for the Global Tumor Genomics Market ....................... 237
Figure 14.73: QIAGEN: Overall Financials, 2016-2018.................................................................... 238
Figure 14.74: QIAGEN: Revenue (by Business Model), 2016-2018................................................ 239
Figure 14.75: QIAGEN: Revenue (by Region), 2016-2018 .............................................................. 240
Figure 14.76: QIAGEN: R&D Expenditure, 2016-2018..................................................................... 241
Figure 14.77: QIAGEN: SWOT Analysis ........................................................................................... 242

Figure 14.78: Siemens Healthineers AG: Product Offerings for the Global Tumor
Genomics Market................................................................................................................... 244
Figure 14.79: Siemens Healthineers AG Overall Financials, 2017-2019......................................... 245
Figure 14.80: Siemens Healthineers AG: Revenue (by Product and Services), 2017-2019........... 246
Figure 14.81: Siemens Healthineers AG: Revenue (by Region), 2017-2019.................................. 247
Figure 14.82: Siemens Healthineers AG: R&D Expenditure, 2017-2019 ........................................ 248
Figure 14.83: Siemens Healthineers AG: SWOT Analysis............................................................... 249
Figure 14.84: Thermo Fisher Scientific Inc.: Product Offerings for the Global Tumor
Genomics Market................................................................................................................... 251
Figure 14.85: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019.................................... 252
Figure 14.86: Thermo Fisher Scientific Inc.: Net Revenue (by Business Segment), 2017-2019... 253
Figure 14.87: Thermo Fisher Scientific Inc.: Net Revenue (by Region), 2017-2019....................... 254
Figure 14.88: Thermo Fisher Scientific Inc.: R&D Expense, 2017-2019.......................................... 255
Figure 14.89: Thermo Fisher Scientific, Inc.: SWOT Analysis.......................................................... 256

BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in
today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates
and institutions worldwide and assist them with market intelligence in the area of emerging
technologies, advisories, and other innovative solutions.
Know More Know More
Know More
Know More

Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in
response to orders. The report is licensed for the customer's internal use only and is subject to
restrictions set henceforth. This document and its contents are confidential and may not be further
distributed, published or reproduced, in whole or in part, by any medium or in any form for any
purpose, without the written consent of BIS Research. The customer will not disclose the contents of
the report, whether directly through any medium or indirectly through incorporation in a database,
marketing list, report or otherwise, or use or permit the use of information to generate any statistical
or other information that is or will be provided to third parties, or voluntarily produce information in
legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information
is available. Any recommendation contained in this report may not be suitable for all investors or
businesses. The market conclusions drawn are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by BIS Research as of the date of such statements,
are inherently subject to market fluctuations and business, economic and competitive uncertainties
and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: info@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544

Global Tumor Genomics Market

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Global Tumor Genomics Market

Similar to Global Tumor Genomics Market (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Global Tumor Genomics Market